Welcome to our dedicated page for AVALYN PHARMACEUTICALS news (Ticker: AVLN), a resource for investors and traders seeking the latest updates and insights on AVALYN PHARMACEUTICALS stock.
Avalyn Pharma Inc. reports news about its clinical-stage development of inhaled therapies for serious, rare respiratory diseases. Recurring company updates cover AP01 and AP02, pulmonary fibrosis research, clinical presentations, peer-reviewed publications, patient-centered treatment research, and respiratory-disease conference activity.
Company news also includes public-company developments such as the closing of its initial public offering, Nasdaq listing of AVLN common stock, capital-structure updates, governance changes, leadership appointments, clinical or regulatory disclosures, and operating and financial results tied to its rare lung disease pipeline.
Avalyn (NASDAQ:AVLN) announced a peer-reviewed publication (BMC Pulmonary Medicine, March 25, 2026) reporting that quantitative HRCT imaging changes with inhaled AP01 (pirfenidone) correlated with lung function and quality-of-life improvements in Phase 1b ATLAS patients.
Key results: >70% of AP01 100 mg BID patients with baseline and Week 24 imaging showed stabilization or improvement in fibrosis score; QOL gains appeared by Week 8 and persisted to Week 48. Avalyn plans HRCT in upcoming Phase 2 MIST and AURA trials; additional longitudinal data expected mid-2026.